Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE.
ACTIDIL vs DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Competitive antagonist of histamine H1 receptors; centrally acting anticholinergic agent that inhibits acetylcholine muscarinic receptors.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
25 to 50 mg intravenously or intramuscularly every 4 to 6 hours as needed; maximum 400 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Terminal elimination half-life: 4-10 hours (mean ~8 hours); prolonged in hepatic impairment or elderly (up to 20 hours).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily renal as inactive metabolites; ~60% of a dose appears in urine as metabolites, with <5% unchanged. Minor biliary/fecal elimination (<10%).
Category C
Category A/B
Antihistamine
Antihistamine